Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy

Journal of Thrombosis and Thrombolysis

Volumn 30, Issue 4, 2010, Pages 446-451

  Parodi, Guido ^a   De Luca, Giuseppe ^a,b   Moschi, Guia ^a   Bellandi, Benedetta ^a   Valenti, Renato ^a   Migliorini, Angela ^a   Carrabba, Nazario ^a   Antoniucci, David ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

Author keywords

Abciximab; Acute myocardial infarction; Anticoagulation; Platelets; Stent

Indexed keywords

ABCIXIMAB; ANTICOAGULANT AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PROTAMINE;

AGED; ARTICLE; COMPARATIVE STUDY; DRUG COMBINATION; FEMALE; HEART INFARCTION; HUMAN; MALE; MIDDLE AGED; POSTOPERATIVE HEMORRHAGE; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POSTOPERATIVE HEMORRHAGE; PROTAMINES; TIME FACTORS;

EID: 80053355191     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-010-0481-5     Document Type: Article

References (25)

1. Topol EJ, Neumann F-J, Montalescot G (2003) A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol 42:1886-1889
2. Brener SJ, Barr LA, Burchenal JE, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topol EJ (1998) Randomized, placebocontrolled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction; Reopro and Primary PTCA Organization and Randomized trial (RAPPORT) Investigators. Circulation 98:734-741
3. Neumann F-J, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, Gawaz M, Schleef M, Seyfarth M, Dirschinger J, Schomig A (2000) Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 35:915-921
4. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton p (2001) Abciximab before direct angioplasty and stenting in myocardial infarction regarding acute and longterm follow-up. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 344:1895-1903
5. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Guagliumi G, Stuckey T, Turco M, Carroll JD, Rutherford BD, Lansky AJ (2002) Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigator. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarctions. N Engl J Med 346:957-966
6. Antoniucci D, Rodriguez A, Hempel A, Valenti R, Migliorini A, Vigo F, Parodi G, Fernandez-Pereira C, Moschi G, Bartorelli A, Santoro GM, Bolognese L, Colombo A (2003) A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol 42:1879-1885
7. EPIC investigators (1994) Use of the monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med 330:956-961
8. Stone GW, Bertrand M, Colombo A, Dangas G, Farkouh ME, Feit F, Lansky AJ, Lincoff AM, Mehran R, Moses JW, Ohman M, White HD (2004) Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: Study design and rationale. Am Heart J 148:764-775
9. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P (1987) The thrombolysis in myocardial infarction (TIMI) trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76:142-154
10. EPILOG investigators (1997) Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 336:1689-1696
11. Rao SV, O'Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, Moliterno DJ, Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Harrington RA (2006) A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol 47:809-816
12. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ, REPLACE-2 Investigators (2003) Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853-863
13. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE, Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM, ACUITY Investigators (2006) Bivalirudin for patients with acute coronary syndromes. N Engl J Med 355:2203-2216
14. Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW (2009) HORIZONS-AMI Trial Investigators. Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. Lancet 374:1149-1159
15. Jaques LB (1973) Protamine antagonist to heparin. J Can Med Assoc 108:1291-1297
16. Horrow JC (1985) Protamine: A review of its toxicity. Anesth Analg 64:348-361
17. Click RL, Hamburger HA, Bove AA (1989) Complement activation from protamine sulfate after coronary angiography. Cathet Cardiovasc Diagn 16:221-225
18. Evora PRB, Pearson PJ, Schaff HV (1995) Protamine indices endotheliumdependent vasodilatation of the pulmonary artery. Ann Thorac Surg 60:405-410
19. Pan M, Suarez de Lezo J, Medina A, Romero M, Hernandez E, Segura J, Melian F, Wanguemert F, Landin M, Benitez F, Amat M, Velasco F, Torres A (1997) In-laboratory removal of femoral sheath following protamine administration in patients having intra-coronary stent implantation. Am J Cardiol 80:1336-1338
20. Ducas J, Chan MC, Miller A, Kashour T (2002) Immediate protamine administration and sheath removal following percutaneous coronary intervention: A prospective study of 429 patients. Catheter Cardiovasc Interv 56:196-199
21. Briguori C, Di Mario C, De Gregorio J, Sheiban I, Vaghetti M, Colombo A (1999) Administration of protamine after coronary stent deployment. Am Heart J 138:64-68
22. Thuesen L, Andersen HR, Bøtker HE, Dalby Kristensen S, Krusell LR, Lassen JF (2005) In-laboratory femoral sheath removal after heparin reversal by protamine after percutaneous coronary intervention. EuroIntervention 1:66-69
23. Parodi G, Migliorini A, Valenti R, Bellandi B, Signorini U, Moschi G, Buonamici P, Cerisano G, Antoniucci D (2010) Comparison of bivalirudin and unfractionated heparin plus protamine in patients with coronary heart disease undergoing percutaneous coronary intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] Trial). Am J Cardiol 105:1053-1059
24. Montalescot G, Wiviott SD, Braunwald E, Murphy SA, Gibson CM, McCabe CH, Antman EM (2009) TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): Double-blind, randomised controlled trial. Lancet 373:723-731
25. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M, PLATO Investigators (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361:1045-1057